Literature DB >> 33185912

Gut microbiota and metabolome distinctive features in parkinson disease: Focus on levodopa and levodopa carbidopa intrajejunal gel.

Marta Melis1, Sarah Vascellari2, Maria Laura Santoru3, Valentina Oppo4, Margherita Fabbri5, Marianna Sarchioto6, Daniela Murgia4, Maurizio Zibetti5, Leonardo Lopiano5, Alessandra Serra2, Vanessa Palmas2, Silvia Pisanu2, Daniela Perra2, Veronica Madau2, Roberto Cusano7, Paolo Uva7, Alessandra Mereu8, Paolo Contu8, Micaela Morelli9, Luigi Atzori3, Maurizio Melis4, Aldo Manzin2, Giovanni Cossu4.   

Abstract

BACKGROUND: Recent data suggest that imbalances in the composition of the gut microbiome (GM) could exacerbate the progression of Parkinson's Disease (PD). The effect of Levodopa (LD) has been poorly assessed and those of LD-carbidopa intestinal gel (LCIG) have not been evaluated so far. The aim of this study was to identify the effect of LD and, in particular, LCIG on GM and metabolome.
METHODS: Faecal DNA samples from 107 patients with clinical diagnosis of PD were analyzed by next-generation-sequencing of V3 and V4 regions of the 16S rRNA gene. PD patients were classified in different groups: patients on LCIG (LCIG-Group) (n= 38) and on LD (LD-Group) (n= 46). We also included a group of patients (n = 23) without antiparkinsonian medicaments (Naïve-Group). Faecal metabolic extracts were evaluated by Gas Chromatography Mass Spectrometry (GC-MS).
RESULTS: The multivariate analysis showed a significant higher abundance in the LCIG-Group of Enterobacteriaceae, Escherichia and Serratia compared to LD-Group. Compared to Naïve-Group, the univariate analysis showed a reduction of Blautia, Lachnospirae in LD-Group. Moreover, an increase of Proteobacteria, Enterobacteriaceae and a reduction of Firmicutes, Lachnospiraceae and Blautia was found in the LCIG- Group. No significant difference was found in the multivariate analysis of these comparisons. The LD-Group and LCIG-Group were associated to a metabolic profile linked to gut inflammation.
CONCLUSION: Our results suggest that LD and mostly LCIG might significantly influence the microbiota composition and host/bacteria metabolism acting as stressors in precipitating a specific inflammatory intestinal microenviroment, potentially related to the PD state and progression. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Duodopa; LCIG; Levodopa; Parkinson; microbiota

Year:  2020        PMID: 33185912     DOI: 10.1111/ene.14644

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  Gut Microbiota Markers and Dietary Habits Associated with Extreme Longevity in Healthy Sardinian Centenarians.

Authors:  Vanessa Palmas; Silvia Pisanu; Veronica Madau; Emanuela Casula; Andrea Deledda; Roberto Cusano; Paolo Uva; Andrea Loviselli; Fernanda Velluzzi; Aldo Manzin
Journal:  Nutrients       Date:  2022-06-12       Impact factor: 6.706

2.  Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.

Authors:  Federica Garrì; Francesco Paolo Russo; Tommaso Carrer; Luca Weis; Francesca Pistonesi; Michele Mainardi; Michele Sandre; Edoardo Savarino; Fabio Farinati; Francesca Del Sorbo; Paola Soliveri; Daniela Calandrella; Roberta Biundo; Miryam Carecchio; Anna Lena Zecchinelli; Gianni Pezzoli; Angelo Antonini
Journal:  J Neurol       Date:  2022-07-25       Impact factor: 6.682

3.  A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease.

Authors:  Paola Di Carlo; Nicola Serra; Rosa Alduina; Riccardo Guarino; Antonio Craxì; Anna Giammanco; Teresa Fasciana; Antonio Cascio; Consolato M Sergi
Journal:  Front Physiol       Date:  2022-08-30       Impact factor: 4.755

4.  Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.

Authors:  Can Cui; Yingying Han; Hongxia Li; Hongxiang Yu; Bei Zhang; Gang Li
Journal:  Front Cell Infect Microbiol       Date:  2022-08-10       Impact factor: 6.073

Review 5.  Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease.

Authors:  Sujith Pavan; Arvind N Prabhu; Sankar Prasad Gorthi; Bhabatosh Das; Ankur Mutreja; Vignesh Shetty; Thandavarayan Ramamurthy; Mamatha Ballal
Journal:  Folia Microbiol (Praha)       Date:  2022-05-18       Impact factor: 2.629

6.  The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.

Authors:  Michal Lubomski; Xiangnan Xu; Jean Y H Yang; Carolyn M Sue; Ryan L Davis; Andrew J Holmes
Journal:  J Neurol       Date:  2021-06-15       Impact factor: 6.682

Review 7.  New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.

Authors:  Marina Lorente-Picón; Ariadna Laguna
Journal:  Biomolecules       Date:  2021-03-15

Review 8.  The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.

Authors:  Emily M Klann; Upuli Dissanayake; Anjela Gurrala; Matthew Farrer; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Volker Mai; Vinata Vedam-Mai
Journal:  Front Aging Neurosci       Date:  2022-01-07       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.